Warburg Research disclosed Fresenius (ETR:FRE), boosting its stock price target to 73.40EUR earlier today
- Updated: September 16, 2016
Boasting a price of 70.37EUR, Fresenius (ETR:FRE) traded 0.00% even on the day. With the last stock price up 0.00% relative to the two hundred day moving average, compared with the S&P 500 which has decreased -0.01% over the same time period. The company has recorded a 50-day average of 0.00EUR and 200-day moving average of 0.00EUR. Trading volume was held steady, with 0 shares of FRE changing hands on par with the typical 0 shares.
Warburg Research upped the price target of Fresenius (ETR:FRE) to 73EUR, indicating a possible upside of 0.04%,
On 9/15/2016, Warburg Research reported about Fresenius(ETR:FRE) upped the target price from 0.00EUR to 73.40EUR. At the time, this suggested an upside of 0.04%.
With a market capitalization of 0.0 EUR, Fresenius has a price-earnings of 0 with a one-year low of 0.00EUR and a one-year high of 0.00EUR.
Brief Synopsis About Fresenius (ETR:FRE)
Fresenius SE & Co KGaA is a health care company. It operates in the healthcare sector and offers products and services for dialysis, hospitals and outpatient medical care. It focuses on the hospital operations and offers engineering and services for hospitals and other health care facilities. The Company’s operating segments include Fresenius Medical Care; Fresenius Kabi; Fresenius Helios and Fresenius Vamed. The Fresenius Medical Care segment provides dialysis care and dialysis products for patients with chronic kidney failure. The Fresenius Kabi segment is engaged in provision of intravenously administered drugs (IV drugs), infusion therapies, and clinical nutrition and outpatient care. The Fresenius Helios segment is a private hospital operator and operates 72 clinics. The Fresenius Vamed segment provides engineering and services for hospitals and other health care facilities internationally.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.